SCHEMBL27217295

SCHEMBL27217295

Cn1nc(Br)nc1-c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
PSEN1 P49768 2/20 0.40
PSEN2 P49810 2/20 0.40
APH1B Q8WW43 2/20 0.40
NCSTN Q92542 2/20 0.40
APH1A Q96BI3 2/20 0.40
PSENEN Q9NZ42 2/20 0.40
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
AHR P35869 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
MAPK14 Q16539 2/20 0.37
SCN4A P35499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27217120 0.81 NR1H3 (0.58) NPC1RAB9ANR1H2NR1H3KDM4E
SCHEMBL27217204 0.81 NR1H3 (0.63) KDM4CNPC1RAB9ANR1H2NR1H3
SCHEMBL27216894 0.81 SIGMAR1 (0.55) NPC1RAB9ANR1H2NR1H3KDM4E
SCHEMBL9368116 0.79 NPC1 (0.67) KDM4CNPC1RAB9ANR1H2NR1H3
SCHEMBL23130722 0.73 SMN1; SMN2 (0.46) KDM4CNPC1RAB9ANR1H2NR1H3
SCHEMBL12776151 0.71 SIGMAR1 (0.47) KDM4CNPC1RAB9ANR1H2NR1H3
SCHEMBL6915245 0.69 KDM4E (0.48) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL4291353 0.69 CYP1A2 (0.42) NPC1RAB9AMAPTMAPK14HPGD
SCHEMBL15830784 0.69 KDM4C (0.46) KDM4CMEN1TSHRKMT2AMAPK14
SCHEMBL3489083 0.69 SLC34A1 (0.45) KDM4CKDM4EMAPTSMN1; SMN2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 KDM4C 1148/4885NPC1 2558/4885RAB9A 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.